Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2012 Oct 7;18(37):5219-24. doi: 10.3748/wjg.v18.i37.5219.

Effectiveness of infliximab after adalimumab failure in Crohn's disease.

Author information

1
Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28006 Madrid, Spain. mariachs2005@gmail.com

Abstract

AIM:

To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure.

METHODS:

A historical cohort study in a community-based gastroenterology practice evaluated Crohn's disease patients treated with infliximab (induction plus maintenance) after adalimumab failure. Patients were identified using a large Spanish database (ENEIDA).

RESULTS:

We included 15 Crohn's disease patients who received infliximab after adalimumab failure. Five patients discontinued adalimumab due to loss of response, 3 due to adverse events and 7 due to partial response. After infliximab therapy was started, all patients who had interrupted adalimumab due to loss of efficacy regained response. All patients who discontinued adalimumab due to adverse events responded to infliximab and maintained this response; one of these patients had an uneventful course on infliximab, but 2 developed adverse events. None of the 7 patients who interrupted adalimumab due to partial response reached remission with infliximab.

CONCLUSION:

Switching from adalimumab to infliximab may be useful in patients who develop adverse effects or loss of response, however, the benefit of infliximab in primary nonresponders was not established.

KEYWORDS:

Adalimumab; Biologics; Crohn’s disease; Infliximab; Switch

PMID:
23066316
PMCID:
PMC3468854
DOI:
10.3748/wjg.v18.i37.5219
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Support Center